{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:35:47Z","timestamp":1791070547012,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold>A functional link between seizure\u2010induced P\u2010glycoprotein overexpression at the blood\u2013brain barrier and therapeutic failure has been suggested by several studies using rodent epilepsy models and human epileptic tissue. Recently, we reported that interference with the mechanisms that up\u2010regulate P\u2010glycoprotein in response to seizure activity might provide a novel approach to control its expression in the epileptic brain. Based on these data, we hypothesized that blocking the appropriate signalling cascade by cyclooxygenase\u20102 inhibition should improve brain penetration of antiepileptic drugs and help to overcome drug resistance.<\/jats:p><jats:p><jats:bold>Experimental approach:\u2002<\/jats:bold>Effects of the selective cyclooxygenase\u20102 inhibitor celecoxib on the response to the P\u2010glycoprotein substrate, phenobarbital, was evaluated in a chronic model of drug\u2010resistant temporal lobe epilepsy in rats. Drug\u2010resistant rats selected from this model exhibit a marked overexpression of P\u2010glycoprotein in the hippocampus and other limbic brain regions.<\/jats:p><jats:p><jats:bold>Key results:\u2002<\/jats:bold>Responders and non\u2010responders were selected from a group of rats with spontaneous recurrent seizures after prolonged treatment with phenobarbital at maximum tolerated doses. The efficacy of phenobarbital was re\u2010evaluated following a 6 day treatment with celecoxib and the frequency of spontaneous recurrent seizures was significantly reduced in both groups of rats, phenobarbital responders or non\u2010responders selected from the previous drug trial.<\/jats:p><jats:p><jats:bold>Conclusions and implications:\u2002<\/jats:bold>Pretreatment with the cyclooxygenase\u20102 inhibitor restored the anticonvulsant activity of phenobarbital in rats that failed to exhibit a relevant response before celecoxib treatment. Our data provide further support for a novel therapeutic approach to overcome transporter\u2010mediated drug resistance in epilepsies.<\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00765.x","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T11:40:51Z","timestamp":1269258051000},"page":"1062-1071","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy"],"prefix":"10.1111","volume":"160","author":[{"given":"J","family":"Schlichtiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pekcec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Bartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Potschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.041210"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00980.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087872"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.06.014"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.085514"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.132225"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2009.45.2.1322481"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01116.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1728"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2005.04.006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.08.032"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.05172.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152520"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00423-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh682"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0026-895X(25)08713-9","article-title":"Modulators and substrates of P\u2010glycoprotein and cytochrome P4503A coordinately up\u2010regulate these proteins in human colon carcinoma cells","volume":"49","author":"Schuetz EG","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00156-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00298.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00496.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.09.012"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh437"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2003.10.012"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2003.12.009"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.4A6451.2005"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.01.009"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00765.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00765.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:55:42Z","timestamp":1739984142000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00765.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00765.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00765.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,7]]},"assertion":[{"value":"2010-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}